Divalproex Sodium
NDC Package 0245-0182-01
Package Information
Divalproex Sodium is a medication used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. Marketed by Upsher-smith Laboratories, Inc., this product is identified by NDC 0245-0182 and is authorized under FDA application ANDA078182.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0245 - Upsher-smith Laboratories, Inc.
- 0245-0182 - Divalproex Sodium
- 0245-0182-01 - 10 BLISTER PACK in 1 CARTON / 10 TABLET, DELAYED RELEASE in 1 BLISTER PACK (0245-0182-89)
- 0245-0182 - Divalproex Sodium
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0245-0182). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0245-0182-01 identifies a specific commercial package of 10 blister pack in 1 carton / 10 tablet, delayed release in 1 blister pack (0245-0182-89) of Divalproex Sodium, labeled by Upsher-smith Laboratories, Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Upsher-smith Laboratories, Inc. on January 21, 2011. The current certification is valid through June 30, 2016.
What are the primary indications for this medication?
This medication is used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. It works by restoring the balance of certain natural substances (neurotransmitters) in the brain.
How is this Upsher-smith Laboratories, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00245018201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 10 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.